Agios Pharm

NASDAQ AGIO

Data sourced from

and

Download Data

Agios Pharm Dividend Coverage Ratio 2 year CAGR for the quarter ending September 19, 2024

Agios Pharm Dividend Coverage Ratio 2 year CAGR is NA for the quarter ending September 19, 2024. The dividend coverage ratio measures a company's ability to cover its dividend payments with its net income. It is calculated by dividing net income by dividends paid. This ratio indicates the proportion of net income that is allocated to paying dividends. A ratio greater than 1 suggests sufficient income to cover dividend payments, while a ratio less than 1 indicates a potential shortfall. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

NASDAQ: AGIO

Agios Pharm

CEO	Dr. Bruce D. Car DACVP, Ph.D.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees	383
Sector	Healthcare
Industry	Biotechnology

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends